Search This Blog

Tuesday, May 15, 2018

UroGen target upped by Ladenburg

Ladenburg Thalmann raised its price target on UroGen Pharma (NASDAQ: URGN) to $72.00 (from $65.00) while maintaining a Buy rating.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)